MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025. "We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,†said Viktoria Friedrich, Country President and General Manager at Bayer Inc., Pharmaceutical Division. "This partnership w. ...

Core Viewpoint - Bayer is at the forefront of developing innovative cell and gene therapies for Parkinson's disease, which presents both exciting opportunities and significant risks for CEO Bill Anderson as the company faces patent expirations on its blockbuster drugs [1] Group 1 - Bayer's focus on cell and gene therapies highlights its commitment to pioneering treatments in the biopharmaceutical sector [1] - The development of these therapies is seen as a critical test of CEO Bill Anderson's capabilities in leading the company through a transformative period [1] - The impending patent expirations on key products may impact Bayer's revenue streams, making the success of new therapies even more crucial [1]

来源：ESG评级中心 点击查看更多企业ESG评级。 据新浪财经ESG评级中心，2025年09月22日，拜耳（BAYRY.US）MSCI（明晟）ESG评级由A调升至 AA。 ...

Core Insights - Bayer has made significant progress in developing two potential therapies for Parkinson's disease (PD) [1] Group 1: Clinical Trials - The first participant has been randomized in the pivotal Phase III clinical trial, exPDite-2, for bemdaneprocel, which is an investigational cell therapy for PD [1] - The first European participants have been randomized in the Phase II clinical trial, REGENERATE-PD, for AB-1005, an investigational gene therapy [1] - Both therapies are aimed at treating moderate-stage Parkinson's disease [1]

Bayer’s menopause drug won the backing of European regulators, a step toward the rollout of a medicine that reduces hot flashes https://t.co/Z3pxc9ZeI6 ...

Core Insights - Bayer's Aspirina, a leading pain relief brand in Mexico and Latin America, has launched in the United States, aiming to provide familiar and effective pain relief options to the growing Hispanic population [1][2][3] Company Overview - Bayer is a global enterprise focused on health care and nutrition, with a mission of "Health for all, Hunger for none." The company aims to address challenges posed by a growing and aging global population while driving sustainable development and innovation [5] - In fiscal 2023, Bayer employed approximately 100,000 people and reported sales of €47.6 billion, with R&D expenses before special items amounting to €5.8 billion [5] Market Context - The Hispanic population in the U.S. currently represents 19% of the total population and is projected to reach 28% by 2060, highlighting the importance of providing familiar healthcare options [2] - Aspirina has a 99% awareness rate in Mexico, with 67% of consumers using it regularly, indicating strong brand recognition and consumer loyalty [3] Product Availability - Aspirina is available at select Walmart and Walgreens locations in the U.S., making it accessible for families seeking familiar pain relief solutions [3]

Core Insights - Bayer has announced a milestone in its Take Care, Now campaign in collaboration with country superstar Luke Bryan and Feeding America, focusing on addressing food insecurity and nutrient gaps [1] Company Initiatives - The campaign builds on last year's success and aims to tackle both food insecurity and "hidden hunger," which refers to nutrient deficiencies that can affect long-term health despite adequate caloric intake [1] - This year's initiative includes a new component to celebrate the 10th anniversary of the campaign [1]

Market Overview - European markets showed positive movement on Monday afternoon, driven by investor optimism regarding a potential rate cut by the Federal Reserve [1] - The pan-European Stoxx 600 index increased by 0.43%, with Germany's DAX up 0.15% and France's CAC 40 gaining 1.1% [2] Sector Performance - In the French market, Kering was the top performer, rising nearly 5%, followed by Thales and Societe Generale with increases of 4% and 3.6% respectively [3] - In Germany, Sartorius climbed nearly 3%, while several other companies including Rheinmetall and Infineon saw gains between 1% and 2.5% [4] - The UK market saw Sainsbury (J) increase by about 4.7%, while Centrica surged 3.5% [5] Economic Indicators - The euro area trade surplus decreased to EUR 12.4 billion in July from EUR 18.5 billion a year earlier, although it was above June's level of EUR 8 billion [7] - Annual export growth in the euro area halved to 0.4% in July, while imports rose by 3.1% [7] - Germany's wholesale price inflation accelerated to 0.7% in August, driven by higher food and non-ferrous ores [8]

Core Viewpoint - Corteva is reportedly considering splitting into two separate companies, which has led to a rise in its shares during premarket trading [1][3]. Company Background - Corteva was established in 2018 as the agricultural division of the merged DowDuPont and became an independent entity in 2019 through a three-way spinoff involving Corteva, DuPont, and Dow [2]. - The company, along with Bayer, holds a dominant position in the U.S. corn and soybean seed market [2]. Strategic Considerations - The potential split may be motivated by a desire to mitigate risks associated with pesticide lawsuits, similar to those faced by Bayer regarding its Roundup weedkiller [2][3]. - Corteva shares have increased approximately 30% year-to-date, indicating positive market sentiment leading up to the potential announcement [3].

Group 1 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is considered a promising investment opportunity, with a Buy rating and a price target of $640.00 set by BMO Capital analyst Evan Seigerman [1][2] - The company has shown promising results from recent Phase 3 trials for its cat and birch allergy antibody cocktails, indicating significant symptom reductions in patients [2][3] - The clinical efficacy demonstrated in these trials suggests that Regeneron's products could address a substantial unmet need in allergy treatment [3] Group 2 - Regeneron has primarily relied on two key products, Dupixent and Eylea, for revenue growth in recent years [4] - Dupixent is an eczema treatment developed in collaboration with Sanofi, while Eylea is used for treating wet age-related macular degeneration and is co-marketed with Bayer [4]